Interleukin 28B Genetic Polymorphisms Play a Minor Role in Identifying Optimal Treatment Duration in HCV Genotype 1 Slow Responders to Pegylated Interferon plus Ribavirin

Abstract

Background

Pegylated interferon and ribavirin for 72 weeks improve sustained virological response (SVR) in HCV genotype 1 (HCV-1) slow viral responders. Whether interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and on-treatment viral responses can identify non-rapid virological response (RVR) patients who benefit from 48 or 72 weeks of therapy remains unclear.

Methods

Treatment-naive HCV-1 patients who failed to achieve RVR were randomly assigned to receive 48 (n=168) or 72 (n=167) weeks of therapy. Baseline factors and on-treatment virological responses at weeks 8 and 12 were evaluated for SVR in 289 compliant patients who received ≥80% of drug dosages and treatment duration, and had end of follow-up viral response. The stratified SVR rates for independent factors were compared by treatment duration.

Results

Treatment duration, IL28B rs8099917 genotypes, cirrhosis, week-8 viral response (undetectable HCV RNA at treatment week 8) and complete early virological response (cEVR) predicted SVR. In week-8 viral response patients, the SVR rates of 72-week and 48-week treatment were similar (75–88%), regardless of IL28B SNP genotypes or cirrhosis. In non-week-8 viral response patients who achieved cEVR, the SVR rate of 72-week treatment was higher than that of 48-week treatment for non-cirrhotic patients, regardless of IL28B SNP genotypes (91–100% versus 13–44%; P=0.001).

Conclusions

Although IL28B SNP genotypes predict SVR, they play a minor role when on-treatment viral responses are taken into consideration. On-treatment viral responses at weeks 8 and 12 are the key determinants to decide the optimal treatment duration in HCV-1 patients without RVR.

References

Rosen

H.R.

Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011; 364: 2429–2438.

Manns

M.P.

, McHutchison

J.G.

, Gordon

S.C.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.

Fried

M.W.

, Shiffman

M.L.

, Reddy

K.R.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

Hadziyannis

S.J.

, Sette

Jr. , Morgan

T.R.

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.

McHutchison

J.G.

, Lawitz

E.J.

, Shiffman

M.L.

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580–593.

Ferenci

, Laferl

, Scherzer

T.M.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451–458.

Mangia

, Minerva

, Bacca

Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47: 43–50.

M.L.

, Dai

C.Y.

, Huang

J.F.

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884–1893.

Liu

C.H.

, Liu

C.J.

, Lin

C.L.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260–1269.

10.

Sánchez-Tapias

J.M.

, Diago

, Escartín

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451–460.

11.

Buti

, Lurie

, Zakharova

N.G.

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52: 1201–1207.

12.

Ferenci

, Laferl

, Scherzer

T.M.

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138: 503–512.

13.

Di Martino

, Richou

, Cervoni

J.P.

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54: 789–800.

14.

Mangia

, Andriulli

Tailoring the length of antiviral treatment for hepatitis C. Gut 2010; 59: 1–5.

15.

Poordad

, McCone

Jr. , Bacon

B.R.

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–1206.

16.

Bacon

B.R.

, Gordon

S.C.

, Lawitz

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207–1217.

17.

Jacobson

I.M.

, McHutchison

J.G.

, Dusheiko

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–2416.

18.

Zeuzem

, Andreone

, Pol

Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417–2428.

19.

Sherman

K.E.

, Flamm

S.L.

, Afdhal

N.H.

Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014–1024.

20.

Ghany

M.G.

, Strader

D.B.

, Thomas

D.L.

, Seeff

L.B.

Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–1374.

21.

Thomas

D.L.

, Thio

C.L.

, Martin

M.P.

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798–801.

22.

, Fellay

, Thompson

A.J.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.

23.

Tanaka

, Nishida

, Sugiyama

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–1109.

24.

Suppiah

, Moldovan

, Ahlenstiel

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100–1104.

25.

Thompson

A.J.

, Muir

A.J.

, Sulkowski

M.S.

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120–129.

26.

Stättermayer

A.F.

, Stauber

, Hofer

Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344–350.

27.

Huang

C.F.

, Huang

J.F.

, Yang

J.F.

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012; 56: 34–40.

28.

Liu

C.H.

, Liang

C.C.

, Liu

C.J.

Interleukin 28B genetic polymorphisms and viral factors help identify hepatitis C virus genotype 1 patients who benefit from 24 week of peginterferon plus ribavirin therapy. Antivir Ther 2012; 17: 477–484.

29.

Liu

C.H.

, Hsu

S.J.

, Lin

J.W.

Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. Clin Gastroenterol Hepatol 2007; 5: 1199–1206.

30.

Liu

C.H.

, Lin

J.W.

, Tsai

F.C.

Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int 2006; 26: 1087–1094.

31.

Bedossa

, Poynard

An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289–293.

32.

McHutchison

J.G.

, Manns

, Patel

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–1069.

33.

Barrett

J.C.

, Fry

, Maller

, Daly

M.J.

Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.

34.

Shiffman

M.L.

, Salvatore

, Hubbard

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 371–379.

35.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245–264.

36.

Huang

C.F.

, Yang

J.F.

, Dai

C.Y.

Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201: 751–759.

37.

Oze

, Hiramatsu

, Yakushijin

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol 2011; 54: 604–611.

38.

Chayama

, Hayes

C.N.

, Yoshioka

Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. J Gastroenterol 2011; 46: 545–555.

39.

Mangia

, Thompson

A.J.

, Santoro

Limited utility of IL28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011; 54: 772–780.